Evgen Pharma PLC Notification of Preliminary Results (7450B)

TIDMEVG

RNS Number : 7450B

Evgen Pharma PLC

11 June 2019

 
 For immediate release   11 June 2019

Evgen Pharma plc

("Evgen" or "the Company")

Notification of Preliminary Results

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2019 on Thursday 13 June 2019.

Enquiries:

 
 Evgen Pharma plc                                c/o +44 (0) 20 7466 5000 
  Dr Stephen Franklin, CEO 
  Richard Moulson, CFO 
  www.evgen.com 
 finnCap 
  Geoff Nash, Teddy Whiley (Corporate 
  Finance) 
  Alice Lane, Manasa Patil (ECM) 
  www.finncap.com                                    +44 (0) 20 7220 0500 
 WG Partners LLP 
  Nigel Barnes, Claes Spång                     +44 (0) 20 3705 9330 
 Buchanan 
  Mark Court, Sophie Wills, Tilly 
  Abraham 
  evgen@buchanan.uk.com                              +44 (0) 20 7466 5000

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORURSWRKUANAAR

(END) Dow Jones Newswires

June 11, 2019 02:01 ET (06:01 GMT)

Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024